Asset Details
Do you wish to reserve the book?
The Immunomodulatory Effects of Thalidomide on Human Immunodeficiency Virus–Infected Children
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Immunomodulatory Effects of Thalidomide on Human Immunodeficiency Virus–Infected Children
Do you wish to request the book?
The Immunomodulatory Effects of Thalidomide on Human Immunodeficiency Virus–Infected Children
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Immunomodulatory Effects of Thalidomide on Human Immunodeficiency Virus–Infected Children
2001
Overview
The safety and immune effects of low-dose thalidomide treatment (3 mg/kg/day for 28 days) were evaluated in a study involving 8 South African human immunodeficiency virus (HIV)–infected children. The children were 7–69 months old and in disease stages A1–C3. Thalidomide therapy did not affect virus load, even though none of the children was receiving antiretroviral therapy. Thalidomide stimulated CD8+ T cells in peripheral blood, which increased expression of the activation markers CD38 and human leukocyte antigen DR and of the memory cell marker CD45RO. The frequency of HIV gag–specific CD8+ T cells in peripheral blood increased in 3 of 4 children who were evaluated during treatment with thalidomide. Clinical adverse events were mild. In this study, thalidomide was found to be safe and well tolerated and caused significant immunomodulation at a low dose. This is the first report describing use of an oral drug that may enhance HIV-specific CD8+ T cell function in HIV-infected children
Publisher
The University of Chicago Press,University of Chicago Press,Oxford University Press
Subject
/ Anti-HIV Agents - administration & dosage
/ Anti-HIV Agents - adverse effects
/ Anti-HIV Agents - therapeutic use
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Biological and medical sciences
/ Blood
/ CD8-Positive T-Lymphocytes - immunology
/ Female
/ Grade 1
/ HIV
/ HIV Infections - drug therapy
/ Human immunodeficiency virus
/ Humans
/ Infant
/ Male
/ Pharmacology. Drug treatments
/ Thalidomide - administration & dosage
/ Thalidomide - adverse effects
/ Thalidomide - therapeutic use
/ Viral diseases of the lymphoid tissue and the blood. Aids
/ Viruses
